Publications by authors named "Deepak Assudani"

Claim this Profile
P
Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients with Systemic Lupus Erythematosus: A Multicenter, Open-Label Trial.
Hermine I Brunner, Jordi Antón, Inmaculada Calvo-Penadés, Richard Dimelow, Gerd Horneff, Deepak Assudani

Arthritis Care Res (Hoboken)· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE.
Philip J Mease, Akihiko Asahina, Dafna D Gladman, Yoshiya Tanaka, William Tillett, Deepak Assudani

Rheumatology (Oxford)· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).
Iain B McInnes, Akihiko Asahina, Laura C Coates, Robert Landewé, Joseph F Merola, Deepak Assudani

Lancet· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).
Joseph F Merola, Robert Landewé, Iain B McInnes, Philip J Mease, Christopher T Ritchlin, Deepak Assudani

Lancet· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study.
Laura C Coates, Iain B McInnes, Joseph F Merola, Richard B Warren, Arthur Kavanaugh, Deepak Assudani

Arthritis Rheumatol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial.
Christopher T Ritchlin, Arthur Kavanaugh, Joseph F Merola, Georg Schett, Jose U Scher, Deepak Assudani

Lancet· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study.
Stanley B Cohen, Alberto Alonso-Ruiz, Piotr A Klimiuk, Eric C Lee, Nuala Peter, Deepak Assudani

Ann Rheum Dis· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful administration of BI 695501, an adalimumab biosimilar, using an autoinjector (AI): results from a Phase II open-label clinical study (VOLTAIRE-RL).
Stanley Cohen, Piotr A Klimiuk, Tillmann Krahnke, Deepak Assudani

Expert Opin Drug Deliv· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, immunogenicity and persistence of immune response to the combined diphtheria, tetanus, acellular pertussis, poliovirus and Haemophilus influenzae type b conjugate vaccine (DTPa-IPV/Hib) administered in Chinese infants.
Yanping Li, Rong Cheng Li, Qiang Ye, Changgui Li, You Ping Liu, Deepak Assudani

Hum Vaccin Immunother· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects.
Christopher Wynne, Mario Altendorfer, Ivo Sonderegger, Lien Gheyle, Rod Ellis-Pegler, Deepak Assudani

Expert Opin Investig Drugs· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and reactogenicity of the combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b (DTPa-IPV/Hib) vaccine in healthy Vietnamese toddlers: An open-label, phase III study.
Dang Duc Anh, Olivier Van Der Meeren, Naveen Karkada, Deepak Assudani, Ta-Wen Yu

Hum Vaccin Immunother· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.
Sven A Silfverdal, Deepak Assudani, Sherine Kuriyakose, Olivier Van Der Meeren

Hum Vaccin Immunother· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of 3-dose primary vaccination with combined DTPa-HBV-IPV/Hib vaccine in Canadian Aboriginal and non-Aboriginal infants.
David W Scheifele, Murdo Ferguson, Gerald Predy, Meena Dawar, Deepak Assudani

Vaccine· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice.
Rupal Ramakrishnan, Deepak Assudani, Srinivas Nagaraj, Terri Hunter, Hyun-Il Cho

J Clin Invest· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells.
Deepak Assudani, Hyun-Il Cho, Nicholas DeVito, Norma Bradley, Esteban Celis

Cancer Res· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of CD4+ T cell help in cancer immunity and the formulation of novel cancer vaccines.
Deepak P Assudani, Roger B V Horton, Morgan G Mathieu, Stephanie E B McArdle, Robert C Rees

Cancer Immunol Immunother· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunotherapeutic potential of DISC-HSV and OX40L in cancer.
Deepak P Assudani, Murrium Ahmad, Geng Li, Robert C Rees, Selman A Ali

Cancer Immunol Immunother· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis